Elicio Therapeutics
BOSTON, MA, United States · Biotechnology · 42 employees
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elic
Funding history
- Venture - Series Unknown — $6.0M — Mar 2024
- Post-IPO Equity — $6.0M — Mar 2024
- Venture - Series Unknown — $7.0M — Jan 2024
- Post-IPO Equity — $7.0M — Dec 2023
- Venture - Series Unknown — $22.0M — Nov 2022
Recent signals
- Nov 19, 2025: Elicio Therapeutics Appoints Marc J. Wolfgang as Chief Technology Officer
- Mar 24, 2025: Elicio Therapeutics Appoints Preetam Shah as Chief Strategy and Financial Officer
- Jan 30, 2025: Elicio Therapeutics Announces $10.0 Million Registered Direct Offering
- Dec 12, 2024: Launched Elicio Therapeutics Shares Promising Data on ELI-002 Cancer Vaccine at ESMO Immuno-Oncology Congress 2024.
- Jun 28, 2024: Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
- Mar 29, 2024: Raised $6.0M in Venture - Series Unknown
- Mar 19, 2024: Raised $6.0M in Post-IPO Equity
- Jan 05, 2024: Raised $7.0M in Venture - Series Unknown
See plans & pricing → Track Elicio Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.